The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

Cancer

Volumn 110, Issue 5, 2007, Pages 973-979

  Chia, Stephen K ^a   Speers, Caroline H ^a   D'Yachkova, Yulia ^a   Kang, Anna ^a   Malfair Taylor, Suzanne ^a   Barnett, Jeff ^a   Coldman, Andy ^a   Gelmon, Karen A ^a   O'Reilly, Susan E ^a   Olivotto, Ivo A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; Hormone therapy; Metastatic breast cancer; Survival

Indexed keywords

AMINOGLUTETHIMIDE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; DOCETAXEL; ESTROGEN RECEPTOR; FLUOROURACIL; MEGESTROL ACETATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; POPULATION RISK; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; BRITISH COLUMBIA; COHORT STUDIES; DATABASES; DRUG THERAPY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 34548187711     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22867     Document Type: Article

References (17)

1. National Cancer Institute of Canada. Canadian cancer statistics 2006. Available at URL: www.cancer.ca Accessed January 8, 2007.
2. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in the US breast cancer incidence, survival and mortality rates. J Natl Cancer Inst. 1996;88:1571-1579.
3. Parkin DM, Bray FI, Ferlay F, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
4. Hortobagyi GH. Treatment of breast cancer. N Engl J Med. 1998;339:974-984.
5. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and US breast cancer deaths down 25% in year 2000 at ages 20-69 years [letter]. Lancet. 2000;355:1822.
6. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930-942.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Lancet. 1998;351:1451-1467.
9. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of iwo phase III trials. J Clin Oncol. 1996;14:2000-2011.
10. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate following tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000;18:1399-1411.
11. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999;17:1413-1424.
12. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
13. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
14. Jones SE, Erban B, Overmoyer GT, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542-5551.
15. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000. Cancer. 2004;100:44-52.
16. Arveux P, Grosclaude P, Reyrat E, et al. Breast cancer survival in France: a relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centres between 1980 and 1999 [abstract]. Proc Am Soc Clin Oncol. 2003;22:3437a.
17. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24:5091-5097.